Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005

Thorax

Volumn 52, Issue 4, 1997, Pages 342-347

  Dahlén, Barbro ^a   Kumlin, Maria ^b   Ihre, Elisabeth ^a   Zetterström, Olle ^a   Dahlén, Sven Erik ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Allergens; Asthma; BAYx 1005; Leukotriene synthesis inhibition

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; ALLERGEN; LEUKOTRIENE E4; PLACEBO;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRIORITY JOURNAL; PROVOCATION TEST; URINALYSIS;

EID: 0030925781     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.4.342     Document Type: Article

References (30)

1. Dahlén S-E, O'Byrne PM. The eicosanoids: prostaglandins, thromboxane and leukotrienes. In: Pauwels R, O'Byrne PM, eds. Anti-asthma drugs. London: WB Saunders, 1997 (in press).
2. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995;8:1203-13.
3. Taylor IK, O'Shaoughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204, 219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
4. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
5. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89:104-5.
6. Dahlén B, Björck T, Zetterström O, Dahlén S-E. The leukotriene-antagonist ICI-204,219 inhibits allergen-induced airway obstruction in asthmatics. Eur Respir J 1994; 7:324-31.
7. 4 receptor antagonist. N Engl J Med 1990;323:1736-9.
8. 4 receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
9. Robuschi M, Riva E, Fucella LM, Vida E, Barnabe R, Rossi M, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene-antagonist (SK&F104, 353). Am Rev Respir Dis 1992;145:1285-8.
10. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144:957-8.
11. Dahlén B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Zetterström O, et al. The leukotriene-antagonist MK-0679 blocks aspirin-induced airway obstruction induced by bronchial provocation with lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993;6:1018-26.
12. Hatzelman A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAYx 1005 [(R)-2-[4-[quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid] and structurally related compounds. Biochem Pharmacol 1993;45:101-11.
13. Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-4.
14. Gorenne I, Labat C, Gascard JP, Norel X, Müller-Peddinghaus R, Mohrs KH, et al. [(R)2-(4-[quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid] (BAYx 1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther 1994;268:868-72.
15. Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MA, Thompson AM, Carpenter TG, et al. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAYx 1005. Eur J Pharmacol 1994; 258:95-102.
16. Wikström Jonsson E, Dahlén S-E. Interactions between leukotrienes and histamine in the anaphylactic contraction of the guinea pig lung strip. J Pharmacol Exp Ther 1994; 271:615-23.
17. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;i: 5808.
18. 1 in humans. Am Rev Respir Dis 1990;141:1441-5.
19. 4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990; 86:211-20.
20. 4 and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
21. Kumlin M, Dahlén S-E. Characteristics of formation and further metabolism of leukotrienes in the chopped human lung. Biochim Biophys Acta 1990;1044:201-10.
22. 4 elimination and metabolism in man. J Allergy Clin Immunol 1990;85:3-9.
23. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9.
24. Nasser SMS, Bell GS, Hawksworth RJ, Spruce KE, MacMillan R, Williams AJ, et al. Effect of the 5-lipoxygenase inhibitor ZD 2138 on allergen-induced early and late asthmatic responses. Thorax 1994;49:743-8.
25. Friedman BS, Bel EH, Tanaka W, Han YHR, Spector R, Sterk P. The effect of a leukotriene biosynthesis inhibitor (MK-886) on allergen-induced bronchoconstriction and leukotriene production in asthmatic subjects. Am Rev Resptr Dis 1993;147:839-44.
26. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depre M, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
27. Nieminen MM, Lahdensuo A, Kellomaeki L, Karvonen J, Muittari A. Methacholine bronchial challenge using a dosimeter with controlled tidal breathing. Thorax 1988; 43:896-900.
28. 4 in human urine. Clin Exp Allergy 1995;25:467-79.
29. Hills A, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20.
30. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997; 52:348-54.